Abstract
Dopamine is the principal transmitter of several central nervous system pathways originating in the midbrain and critically involved in motor activity, learning and motivation, disruptions of which have been implicated in a number of disorders, including Parkinson disease and schizophrenia. Dopamine played a particularly significant role in the history of neurochemistry. Following a series of investigations between 1957 and 1965, commencing in the laboratory and completed in the clinic, the significance of chemical neurotransmission for normal CNS function was first demonstrated in the case of dopamine.
This is a preview of subscription content, access via your institution.
References
Andén N-E, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314
Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22:666–679
Bannon MJ, Roth RH (1983) Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 35:53–68
Baumeister AA, Francis JL (2002) Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 11:265–277
Belujon P, Grace AA (2017) Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol 20:1036–1046
Bertler Å, Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15:10–11
Birkmayer W, Hornykiewicz O (1961) Der l-3,4-Dioxyphenylalanin (= DOPA)-Effekt bei der Parkinson-Akinese. Wr klin Wschr 73:787–788
Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490–493
Carlsson A (1988) The current status of the dopamine hypothesis. Neuropsychopharmacology 1:179–186
Carlsson A (1998) Arvid Carlsson. In: LR Squire (ed) The history of neuroscience in autobiography. vol 2, pp 28–66. Academic Press, San Diego
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276
Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on the formation of 3-hydroxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140–144
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113:1237–1264
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483
Dale E, Bang-Andersen B, Sánchez C (2015) Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 95:81–97
Davis KL, Kahn R, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486
Degkwitz R, Frowein R, Kulenkampff C, Mohs U (1960) Über die Wirkungen des L-DOPA beim Menschen und deren Beeinflussung durch Reserpin, Iproniazid und Vitamin B6. Klin Wschr 38:120–123
Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64:327–337
Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38:1236–1239
Engel J, Carlsson A (1977) Catecholamines and behavior. Curr Dev Psychopharmacol 4:1–32
Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270
Foley PB (2003) The dopamine and l-DOPA story. In: Beans, roots and leaves. A history of the chemical therapy of parkinsonism. Tectum, Marburg, pp 333–387
Foley PB (2014) Sons and daughters beyond your control: episodes in the prehistory of the attention deficit/hyperactivity syndrome. Atten Defic Hyperact Disord 6:125–151
Foley PB (2019) Psychopharmacology: a brief overview of its history. In: Riederer P, Laux G, Mulsant B, Le W, Nagatsu T (eds) NeuroPsychopharmacotherapy. Springer, Vienna (in press)
Hökfelt T (2010) Looking at neurotransmitters in the microscope. Prog Neurobiol 90:101–118
Horn AS, Snyder SH (1971) Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Natl Acad Sci USA 68:2325–2328
Hornykiewicz O (1992) From dopamine to Parkinson’s disease: a personal research record. In: Samson F, Adelman G (eds) The neurosciences: paths of discovery II. Birkhäuser, Boston, pp 125–147
Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848–851
Kendler KS, Schaffner KF (2011) The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos Psychiatr Psychol 18:41–63
Kety SS (1962) Résumé: I. Biochimie. In: Ajuriaguerra JD (ed) Monoamines et système nerveux central. Symposium Bel-Air, Genève, Septembre 1961. Georg et Cie, Genève, pp 263–268
Ledonne A, Mercuri NB (2017) Current concepts on the physiopathological relevance of dopaminergic receptors. Front Cell Neurosci 11:27
Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180:244–245
Mulinari S (2012) Monoamine theories of depression: historical impact on biomedical research. J Hist Neurosci 21:366–392
Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA (2015) The dopamine theory of addiction: 40 years of highs and lows. Nature Rev Neurosci 16:305–312
Poirier LJ, Sourkes TL (1980) This week’s Citation Classic. Curr Contents 25:14
Raab W (1948) Specific sympathomimetic substance in the brain. Am J Physiol 152:324–339
Randrup A, Munkvad I (1974) Pharmacology and physiology of stereotyped behavior. J Psychiatr Res 11:1–10
Sano I (1960) Biochemistry of the extrapyramidal system. Shinkei Kenkyu no Shimpo (Adv Neurol Sci) 5:42–48
Sano HS (2000) Biochemistry of the extrapyramidal system. Park Rel Disord 6:1–6
Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32:586–587
Sano I, Taniguchi K, Gamo T, Takesada M, Kakimoto Y (1960) Die Katechinamine im Zentralnervensystem. Klin Wschr 38:57–62
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 509:509–522
Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152
Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219
Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376–4380
Sharma A, Couture J (2014) A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 48:209–225
Snyder SH (1982) Schizophrenia. Lancet 2:970–973
Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A (1992) Pharmacologic properties of (–)-3PPP (preclamol) in man. J Neural Transm 88:165–175
Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336
van Rossum JM (1967) The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Neuro-psycho-pharmacology. Proceedings of the fifth international congress of the Collegium Internationale Neuro-psychopharmacologicum, 28th–31st March 1966. Excerpta Medica Foundation, Amsterdam, pp 321–329
van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA (2015) The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol 753:114–126
Vane JR, Wolstenholme GEW, O’Connor M (eds) (1960) CIBA foundation symposium jointly with committee for symposia on drug action on adrenergic mechanisms (28th–31st March 1960). J. & A. Churchill, London
Vogt M (1960) Central adrenergic mechanisms. Chairman’s opening remarks. In: Vane JR, Wolstenholme GEW, O’Connor M (eds) CIBA foundation symposium jointly with committee for symposia on drug action on adrenergic mechanisms (28th–31st March 1960). J. & A. Churchill, London, pp 382–385
Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483–494
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Foley, P.B. Dopamine in psychiatry: a historical perspective. J Neural Transm 126, 473–479 (2019). https://doi.org/10.1007/s00702-019-01987-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-019-01987-0